TIDAL-01 is a cell therapy commercialized by Turnstone Biologics, with a leading Phase I program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of TIDAL-01’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for TIDAL-01 is expected to reach an annual total of $48 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

TIDAL-01 Overview

TIDAL-01 is under development for the treatment of solid tumors, cutaneous, non-cutaneous melanoma, HER2 negative and HER2 positive breast cancer, triple negative breast cancer, metastatic colorectal cancer, non-small cell lung cancer, head and neck cancer squamous cell carcinoma and metastatic uveal melanoma. The therapy comprise of tumor-infiltrating lymphocytes (TILs). It is developed based on TIDAL platform. It is administered through intravenous and parenteral route.

Turnstone Biologics Overview

Turnstone Biologics is a clinical stage biotechnology company that develops tumor-targeted oncolytic vaccine for targeted expression of associated antigens and immunomodulatory agents to treat cancer. It is headquartered in La Jolla, California, the US.
The company reported revenues of (US Dollars) US$19.3 million for the fiscal year ended December 2023 (FY2023), a decrease of 73.7% over FY2022. The operating loss of the company was US$59 million in FY2023, compared to an operating loss of US$31.6 million in FY2022. The net loss of the company was US$55.2 million in FY2023, compared to a net loss of US$30.8 million in FY2022.

For a complete picture of TIDAL-01’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.